Truist Financial Boosts Pediatrix Medical Group (NYSE:MD) Price Target to $18.00

Pediatrix Medical Group (NYSE:MD) had its price objective raised by Truist Financial from $15.00 to $18.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. Truist Financial’s price target indicates a potential upside of 15.61% from the stock’s current price.

Several other equities analysts also recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Macquarie started coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They issued an “outperform” rating and a $18.00 price target on the stock. UBS Group raised their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Finally, StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research note on Wednesday, January 22nd. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.08.

Pediatrix Medical Group Stock Down 9.6 %

Shares of NYSE MD opened at $15.57 on Friday. The company’s 50-day simple moving average is $13.89 and its 200-day simple moving average is $12.99. Pediatrix Medical Group has a 52-week low of $6.62 and a 52-week high of $17.67. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -12.97, a price-to-earnings-growth ratio of 1.74 and a beta of 1.57. The company has a quick ratio of 1.42, a current ratio of 1.60 and a debt-to-equity ratio of 0.81.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.12. The firm had revenue of $502.36 million for the quarter, compared to the consensus estimate of $486.22 million. Pediatrix Medical Group had a negative net margin of 4.92% and a positive return on equity of 15.47%. Equities analysts predict that Pediatrix Medical Group will post 1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Pediatrix Medical Group

A number of institutional investors have recently bought and sold shares of the company. Mackenzie Financial Corp purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $276,000. PharVision Advisers LLC purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $245,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Pediatrix Medical Group by 7.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 256,335 shares of the company’s stock valued at $3,363,000 after acquiring an additional 18,627 shares during the period. Voloridge Investment Management LLC purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $396,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at approximately $132,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.